of a protective relationship with AN (Zfinemap = −4.63, PIP = 0.457, blood plasma protein). This discordant direction between mRNA and protein requires further investigation to refine its biological salience. The power of finemapping to identify causal genes increases when more GReX expression models are included, and thus, tissues were used for finemapping that were not subjected to the marginal TWAS, since removing these would decrease finemapping power. There are three genes (RP13- 28F13.5, NXPE1 and PRKAR2A) without TWAS blood and brain associations. One of these; PRKAR2A, exists in a credible set with four other genes (the same set as the finemapped TREX1), three of which are associated within brain regions. Table 1.Finemapped associationsMolecular nameTissue (finemapped model)Ref nameZfinemapPIPZTWAS (P) -tissueZPWAS (P) -tissueRegionCredible set size (brain/ default)MST1Blood plasma proteinGTEx−4.630.4574.85 (1.2 × 10−6)- hypothalamus – Conditionally independent−3.4787 (5.04 × 10−4) -plasma3: 49 317 941–3: 51 830 833NA/1WDR6Brain dorsolateral prefrontal cortexPsychENCODE6.460.9977.44 (9.96 × 10−14)- cortex – Conditionally independentNA3: 49 317 338–3: 51 828 6351/1RP13-238F13.5Brain spinal cord cervical c-1GTEx5.010.97NANA10: 125 919 795–10: 127 999 4241/1NXPE1TestisGTEx6.021NANA11: 114 833 710–11: 116 383 0641/1C3orf62Brain dorsolateral prefrontal cortexCommonMind Consortium−7.190.423−7.13 (9.71 × 10−13)- cortexNA3: 47 777 774–3: 49 313 9784/384TREX1Brain cortexGTEx−6.950.449−3.2575 (1.1 × 10−3) – Nucleus accumbens basal ganglia−2.1349
